Ribon Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 55

Employees
  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $65M

  • Investors
  • 17

Ribon Therapeutics General Information

Description

Developer of a biopharmaceutical platform intended to block a cancer cell's fundamental ability to survive under stress. The company's platform discovers and develops first-in-class small molecule inhibitors or enzymes in the target family, thereby enabling doctors to help treat patients suffering from cancer.

Contact Information

Website
www.ribontx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 35 Cambridgepark Drive
  • Cambridge, MA 02140
  • United States
+1 (617) 000-0000

Ribon Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ribon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B1) 14-Jul-2021 $65M 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 04-Jan-2019 0000 00000 00000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 10-Oct-2017 $43.5M $43.5M 000.00 Completed Clinical Trials - Phase 1
To view Ribon Therapeutics’s complete valuation and funding history, request access »

Ribon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 64,311,060 $0.000100 $0.04 $0.68 $0.68 1x $0.68 22.85%
To view Ribon Therapeutics’s complete cap table history, request access »

Ribon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biopharmaceutical platform intended to block a cancer cell's fundamental ability to survive under stress.
Drug Discovery
Cambridge, MA
55 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00

000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu f
0000 000000000
Uppsala, Sweden
00 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ribon Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytImmune Sciences Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00000000 000000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000000 00000000 Private Equity-Backed Westport, CT 00 000.00 00000000 000.00
You’re viewing 5 of 48 competitors. Get the full list »

Ribon Therapeutics Patents

Ribon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3159188-A1 Pyridazinones as parp7 inhibitors Pending 30-Oct-2019 0000000000
AU-2020375821-A1 Pyridazinones as parp7 inhibitors Pending 30-Oct-2019 0000000000
US-20210130342-A1 Pyridazinones as parp7 inhibitors Pending 30-Oct-2019 0000000000
AU-2020321956-A1 Heterobicyclic amides as inhibitors of cd38 Pending 31-Jul-2019 0000000000
US-20210032251-A1 Heterobicyclic amides as inhibitors of cd38 Pending 31-Jul-2019 C07D403/04
To view Ribon Therapeutics’s complete patent history, request access »

Ribon Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Victoria Richon Ph.D Chairman of Scientific Advisory Board, President & Chief Executive Officer
Kevin Kuntz Ph.D Chief Drug Development Officer
Sally Johnson Chief People Officer
Gary Sutton JD Chief Business Officer
Tim Mitchison Ph.D Co-Founder and Scientific Advisor
You’re viewing 5 of 15 executive team members. Get the full list »

Ribon Therapeutics Board Members (18)

Name Representing Role Since
Anja König Ph.D Novartis Venture Fund Board Member 000 0000
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
Emma Reeve Self Board Member 000 0000
Eyal Lifschitz Peregrine Ventures Board Member 000 0000
James Audia Ph.D Ribon Therapeutics Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Ribon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ribon Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Avego BioScience Capital Venture Capital Minority 000 0000 000000 0
Avego Management Growth/Expansion Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Monashee Investment Management Hedge Fund Minority 000 0000 000000 0
Peregrine Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »